TCIM

Across TCGA pan-cancer cohorts, TCIM mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TCIM data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TCIM mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TCIM expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

LUAD, CCRCC, and PDAC are the cancer types where TCIM mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	II,III,IV	0.635	0.987	.008	14	view →
CCRCC	DFS	Tertile	All	1.000	0.247	.013	11	view →
PDAC	DFS	Median	II,III,IV	0.263	0.849	.038	6	view →
LSCC	DFS	Tertile	II,III,IV	1.000	0.341	.024	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TCIM–LUAD (DFS)

Open the LUAD breakdown →